September 13, 2004
"The percentage of patients who live for a year after an organ transplant has risen dramatically over the past 15 years, but there has been only modest success in improving the odds of long-term survival," says Anthony S. Fauci, M.D., director of NIAID. "This research consortium will move us closer to minimizing the debilitating, and sometimes fatal, complications of organ transplantation."
"This consortium is part of our increased commitment to clinical research programs in immunology," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "The information generated by this group will not only help us understand how the immune system recognizes and either accepts or rejects transplanted organs, it will also enable us to develop promising approaches to improving graft function and survival."
The consortium will also receive support from two other NIH components, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Heart, Lung and Blood Institute. Funding for the three five-year grants totals an estimated $43 million.
Obstacles to successful organ replacement include genetic incompatibility between donor and recipient and transplant rejection by the recipient's immune system. Also, patients who take immunosuppressive drugs for a long period of time are more susceptible to conditions such as diabetes, high blood pressure, and loss of kidney function.
The consortium will, among other activities, seek to identify genetic factors in patients that could help doctors predict transplant outcomes as well as responses to post-transplant therapy; develop diagnostic tests that enable early detection and ongoing monitoring of immune-related processes; and test the safety and effectiveness of new, less toxic immunosuppressive drugs.
The three institutions in the consortium and the principal investigator at each are:
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Expert: Long-Awaited CDC HIV Report on Conception Options for Serodiscordant Couples Is Disappointing and Confusing|
|This Week in HIV Research: Stable Housing Improves Viral Suppression and CD4 Counts|
|The Curious Case of M184V, Part 1|
|Fat Gains Continue and Lean Mass Falls in Group on Long-Term HIV Therapy|
|Inflammation in the Brain Continues Even With Undetectable Plasma Viral Load|
|This Week in HIV Research: Maintenance Therapy Regimen Containing Lamivudine May Be Viable Option|